Skip to Content

Franklin Biotechnology Discovery Adv FTDZX

Analyst rating as of
NAV / 1-Day Return
158.24  /  2.07 %
Total Assets
1.4 Bil
Adj. Expense Ratio
0.780%
Expense Ratio
0.780%
Fee Level
Below Average
Longest Manager Tenure
23.65 years
Category
Health
Investment Style
Mid Growth
Min. Initial Investment
100,000
Status
Open
TTM Yield
0.00%
Turnover
33%
Premium

Morningstar’s Analysis

Will FTDZX outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

A solid but ultimately undifferentiated offering.

Summary

| |

A capable trio leads Franklin Biotechnology Discovery, but limited resources constrain the extent to which the managers can apply their process, limiting the fund to a Morningstar Analyst Rating of Neutral.

Unlock our full analysis with Morningstar Premium